Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in August 2010, to inform of new safety information and advice about medicines.
|
Date issued
|
Product
|
Safety information
|
|---|---|---|
| 3 August 2010 | Gammanorm (kabiglobulin) (56Kb) |
No longer indicated for prophylaxis of hepatitis A or measles |
| 4-11 August 2010 | Topical ketoprofen | Risk of photosensitivity reactions - Menarini (Powergel) (94Kb) letter sent Aug 4 - Teva (108Kb) letter sent 11 Aug - Sanofi-Aventis (Oruvail Gel) (1628Kb) letter sent 10 Aug |
| 12 August 2010 | Xyrem (sodium oxybate) (82Kb) |
Risk of dosing errors: measuring syringe is uniquely graduated in grams (g) |
| 9 August 2010 | Calcium gluconate injection (859Kb) |
Risk of aluminium exposure: calcium glucoante injection in glass ampoules now contraindicated for use as repeated or prolonged treatment in children younger than age 18 years and in patients with renal impairment, as well as in the preparation of TPN solutions |
| 30 August 2010 | Evicel and Quixil (130Kb) |
Risk of air or gas embolism |
| 31 August 2010 | Enzira (seasonal influenza vaccine) and CSL Biotherapies generic influenza vaccine (471Kb) |
Restriction on use in children younger than age 5 years: risk of febrile convulsions |
